Shield Therapeutics (STX) has found increased haemoglobin levels in patients with chronic iron deficiency anaemia over a 52 week study.
Dr Mark Sampson, Chief Medical Officer of Shield, said "Iron deficiency is a significant and progressive issue in patients with chronic renal disease which has been challenging to treat due to poor compliance with traditional oral iron salts.”
“These results suggest that Feraccru® offers a well-tolerated and effective treatment option which can benefit patients over the long-term."
The Feraccru® AEGIS-CKD study was a pivotal phase III randomized, placebo-controlled, double-blind trial in chronic kidney disease (CKD) patients with iron deficiency anaemia. The study showed that when Feraccru was given 30mg orally twice daily, it resulted in improved haemoglobin levels during the 16 week treatment and over the 36-week open-label follow-up period.
Shares in Shield Therapeutics were up 10% following the announcement of the results of the study
Carl Sterritt, CEO and Founder of Shield, said: "Such positive long-term treatment data for Feraccru® in complex patients with chronic diseases like CKD provides a very promising signal for the future commercial success of Feraccru®.”
“We hope that this positive data provides the necessary evidence to both prescribers and patients with iron deficiency with or without anaemia that Feraccru® offers a simple to administer, well tolerated and efficacious treatment alternative that does not require hospital-based administration."
The WHO found that Iron Deficiency affects a significant part, often a majority, of the population in nearly every country in the world. As well as affecting many children and women in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialized nations.
Feraccru® is already approved and marketed in the European Union and Switzerland, awaiting approval from US Food and Drug Administration.
Follow News & Updates from Shield Therapeutics here: